Overview

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This prospective, multicenter, single arm clinical trial was designed to evaluate the efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Camptothecin
Cetuximab
Irinotecan
Vemurafenib